Travere Therapeutics
TVTX Mid CapHealthcare · Biotechnology
Aggiornato: May 2, 2026, 22:05 UTC
Metriche Chiave
Analisi della Valutazione
Informazioni sull'Azienda
Travere Therapeutics Stock at a Glance
Travere Therapeutics (TVTX) is currently trading at 37,64 € with a market capitalization of 3,5 Mrd. €. The 52-week range spans from 11,84 € to 38,13 €; the current price is 1.3% below the yearly high. Year-over-year revenue growth stands at +73.4%.
💰 Dividendo
Travere Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Raccomandazioni degli Analisti
14 analysts rate Travere Therapeutics (TVTX) on consensus: Acquisto Forte. The average price target is 42,34 €, implying +12.52% from the current price. Analyst price targets range from 34,12 € to 47,77 €.
Tesi di Investimento: Punti di Forza e Debolezze
- Strong revenue growth of 73.4% YoY
- High gross margin of 55.91% — indicates pricing power
- Analyst consensus: Strong Buy
- –Currently unprofitable
- –High leverage (D/E 286.28)
- –High short interest (18.05%)
- –Negative free cash flow
- –Price near 52-week high — limited upside cushion
Panoramica Tecnica
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profilo di Rischio
The data points to relatively defensive market behavior, elevated short interest (18.05%), higher leverage relative to equity.
Dati di Trading
Azioni Correlate nello Stesso Settore
Where can I buy Travere Therapeutics?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
